Vincerx Pharma Inc. (VINC)
0.77
-0.32 (-29.36%)
At close: Mar 03, 2025, 3:59 PM
0.79
3.16%
After-hours: Mar 03, 2025, 05:59 PM EST
No 1D chart data available
| Bid | 0.77 |
| Market Cap | 1.71M |
| Revenue (ttm) | 64.43K |
| Net Income (ttm) | -1.33M |
| EPS (ttm) | -17.2 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | -2.59 |
| Analyst | Buy |
| Ask | 0.8 |
| Volume | 425,119 |
| Avg. Volume (20D) | 883,631 |
| Open | 0.79 |
| Previous Close | 1.09 |
| Day's Range | 0.75 - 0.95 |
| 52-Week Range | 0.75 - 187.44 |
| Beta | 1.11 |
About VINC
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat sol...
Industry Biotechnology
Sector Healthcare
IPO Date May 27, 2020
Employees 42
Stock Exchange NASDAQ
Ticker Symbol VINC
Website https://vincerx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for VINC stock is "Buy." The 12-month stock price forecast is $40, which is an increase of 5128.76% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago
-5.45%
Vincerx Pharma shares are trading higher after the...
Unlock content with
Pro Subscription
1 month ago
+15.7%
Vincerx Pharma shares are trading lower after the company announced a 1-for-20 reverse stock split.
